BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26980030)

  • 21. Desmoplastic melanoma with sarcomatoid dedifferentiation.
    Kiuru M; McDermott G; Berger M; Halpern AC; Busam KJ
    Am J Surg Pathol; 2014 Jun; 38(6):864-70. PubMed ID: 24618614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desmoplastic melanoma: a challenge for the oncologist.
    Manfredini M; Pellacani G; Losi L; Maccaferri M; Tomasi A; Ponti G
    Future Oncol; 2017 Feb; 13(4):337-345. PubMed ID: 27728982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
    Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
    J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma.
    Barr J; Amato CM; Robinson SE; Kounalakis N; Robinson WA
    Melanoma Res; 2012 Feb; 22(1):92-5. PubMed ID: 22189301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of BRAF Subcellular Localization and Its Interaction with
    Beleaua MA; Jung I; Braicu C; Milutin D; Gurzu S
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differing biologic behaviors of desmoplastic melanoma subtypes: Insights based on histopathologic, immunohistochemical, and genetic analyses.
    Yang K; Mahalingam M
    J Am Acad Dermatol; 2020 Aug; 83(2):523-531. PubMed ID: 32068045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
    Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
    Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation testing in melanoma: results from a German observational multicenter study.
    Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
    Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.
    Feller JK; Yang S; Mahalingam M
    Mod Pathol; 2013 Mar; 26(3):414-20. PubMed ID: 23041829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of SDHD promoter mutations in various types of melanoma.
    Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
    Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
    Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
    Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
    Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of distinct molecular profile of Primary Dermal Melanoma.
    Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
    Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.